Videos

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss visual snow syndrome and whether it should be evaluated during standard in-clinic ophthalmologic testing.

After a brief hiatus during the pandemic, the Flying Eye Hospital program returns.

Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.

At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.

Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.

Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.

Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Tocilizumab and the influence it can have on ophthalmic outcomes in giant cell arteritis.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, talk about the potential cost savings as well as other real-world implications associated with the use of biosimilars in clinical practice.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, caution against the ophthalmic use of biosimilar products approved for systemic use. They also review how indications for biosimilars are granted upon approval.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, review clinical trial data for biosimilar products, with interpretation of safety data when comparing to the biologic reference products.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, discuss how evolving understanding regarding bioequivalence and the safety of biosimilars may lead to their wider use in the treatment of retinal disorders.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, share historical perspective on the safety of biosimilars and their use in medicine.

Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.

At the recent ASRS meeting in New York, Aleksandra Rachitskaya, MD, of the Cleveland Clinic Cole Eye Institute, presented End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD.

Matthew Emanuel, MD, of Glaucoma Associates of Texas, discusses some of the current trends in cataract surgery. He notes it is something that everyone deals with as they get older. It also can be an issue for pediatric patients. Emanuel also notes that it is important for physicians to be able to educate their patients on the disease.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, review the regulatory oversight process regarding biosimilars after they have entered the market.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, provide an overview of the development and clinical evaluation of biosimilar agents.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Nadia K. Waheed, MD, MPH, and David M. Brown, MD, discuss the future of intravitreal injections.

Expert ophthalmologists discuss absolute contraindications to intravitreal injections and how to manage patients with contraindications.

Gareth Lema, MD, PhD, discusses an innovative eye stroke program at Mount Sinai Health System that involves collaboration among ophthalmologists, the stroke service, and emergency department physicians.

Nadia K. Waheed, MD, MPH, and David M. Brown, MD, provide expert advice on techniques to numb the eye before intravitreal injections.